Published in Curr Top Microbiol Immunol on January 01, 2007
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 2.80
How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol (2009) 2.46
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood (2012) 1.94
A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity (2011) 1.94
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol (2009) 1.31
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res (2009) 1.31
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest (2012) 1.07
Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol (2010) 1.07
NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol (2011) 1.05
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol (2010) 1.04
Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer (2010) 0.97
Synthesis and evaluation of 3''- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000. Bioorg Med Chem Lett (2009) 0.96
Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin Immunol (2008) 0.95
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol (2008) 0.92
Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol (2009) 0.90
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 0.90
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol (2014) 0.89
CD1d activation and blockade: a new antitumor strategy. J Immunol (2009) 0.87
Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res (2014) 0.84
Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH. Bioorg Med Chem Lett (2009) 0.84
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine (2011) 0.80
Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy. Cancers (Basel) (2011) 0.79
Immunology of tuberculosis. World J Exp Med (2012) 0.79
Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function. Int Immunopharmacol (2013) 0.78
Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis. World J Gastroenterol (2007) 0.77
IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clin Transl Immunology (2013) 0.76
Alteration of CD1 expression in multiple sclerosis. Clin Exp Immunol (2012) 0.76
CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia. Oncol Lett (2014) 0.75
Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice. Int J Nanomedicine (2015) 0.75
Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment. Oncotarget (2016) 0.75
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med (1998) 3.34
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol (2001) 2.71
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
The thymic microenvironment. Immunol Today (1993) 2.36
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
CD1d-restricted NKT cells: an interstrain comparison. J Immunol (2001) 1.88
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Cytokine production by mature and immature CD4-CD8- T cells. Alpha beta-T cell receptor+ CD4-CD8- T cells produce IL-4. J Immunol (1992) 1.80
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74
Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes (1997) 1.74
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 1.58
Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci U S A (1992) 1.55
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family. Clin Exp Immunol (2009) 1.52
Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med (1999) 1.45
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol (2001) 1.40
Thymic emigration: conveyor belts or lucky dips? Immunol Today (1995) 1.37
A central role for thymic emigrants in peripheral T cell homeostasis. Proc Natl Acad Sci U S A (1999) 1.37
Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem (1998) 1.36
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Recent thymic emigrants are distinct from most medullary thymocytes. Eur J Immunol (1997) 1.30
Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med (1990) 1.24
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 1.19
Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem (1996) 1.17
A cell line that can induce thymocyte positive selection. Nature (1992) 1.16
Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody. Biochem Biophys Res Commun (1993) 1.14
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
p53-dependent ceramide response to genotoxic stress. J Clin Invest (1998) 1.11
Isolation of a cDNA encoding thymic shared antigen-1. A new member of the Ly6 family with a possible role in T cell development. J Immunol (1993) 1.10
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol (2001) 1.07
Exploration of the Common Bile Duct for Stone. Drainage with T-Tube and Cholangiography. Br Med J (1941) 1.07
CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today (1999) 1.07
Evolution in action. Nature (1974) 1.06
NK cells and apoptosis. Immunol Cell Biol (1999) 1.04
Thymic T cell export is not influenced by the peripheral T cell pool. Eur J Immunol (1997) 1.04
Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol (2000) 1.02
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 1.00
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood (2000) 1.00
GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol (2001) 1.00
NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens (2002) 0.99
A role for P-glycoprotein in regulating cell death. Leuk Lymphoma (2000) 0.99
Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res (1999) 0.99
P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ (2002) 0.97
Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ (2004) 0.96
Granule serine proteases are normal nuclear constituents of natural killer cells. J Biol Chem (1994) 0.95
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol (2000) 0.94
Automated single-cell manipulation and sorting by light trapping. Appl Opt (1987) 0.93
Intrathymic T cell development and selection proceeds normally in the absence of glucocorticoid receptor signaling. Immunity (2000) 0.93
Bcl-2 acts upstream of the PARP protease and prevents its activation. Cell Death Differ (1997) 0.92
Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol (1992) 0.92
Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ (1998) 0.92
Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody. Cell Immunol (1994) 0.91
The restricted expression of granzyme M in human lymphocytes. J Immunol (2001) 0.91
Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J Immunol (1994) 0.90
Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. Cell Death Differ (2000) 0.90
The subunit structure of the aliphatic amidase from Pseudomonas aeruginosa. Eur J Biochem (1973) 0.90
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol (2014) 0.89
Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther (2010) 0.89
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia (2010) 0.89
Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol (1998) 0.88
Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol (2001) 0.88
Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res (1998) 0.87
Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med (2000) 0.87
The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics (1994) 0.86
m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med (1999) 0.85
A lymphostromal molecule, thymic shared Ag-1, regulates early thymocyte development in fetal thymus organ culture. J Immunol (1993) 0.84
Killing by cytotoxic T cells and natural killer cells: multiple granule serine proteases as initiators of DNA fragmentation. Immunol Cell Biol (1993) 0.83
Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther (2007) 0.83
Purification and cloning of a novel serine protease, RNK-Tryp-2, from the granules of a rat NK cell leukemia. J Immunol (1994) 0.82
Expression of human perforin in a mouse cytotoxic T lymphocyte cell line: evidence for perturbation of granule-mediated cytotoxicity. J Leukoc Biol (1993) 0.82
Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets. Clin Exp Immunol (2013) 0.82
T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukoc Biol (2000) 0.81
Five novel antigens illustrate shared phenotype between mouse thymic stromal cells, thymocytes, and peripheral lymphocytes. Int Immunol (1992) 0.81
Role of CD2 in regulation of CD3- LGL function. Eur Cytokine Netw (1991) 0.81
CD38 expression on mouse T cells: CD38 defines functionally distinct subsets of alpha beta TCR+CD4-CD8- thymocytes. Int Immunol (1995) 0.81
P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. J Biol Chem (2001) 0.81
Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol (1995) 0.80
Increased thymic B cells but maintenance of thymic structure, T cell differentiation and negative selection in lymphotoxin-alpha and TNF gene-targeted mice. Dev Immunol (2000) 0.80
Chemoimmunoconjugates for the treatment of cancer. Adv Immunol (1994) 0.80
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther (2008) 0.80
Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunol Immunother (1999) 0.79
Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. J Leukoc Biol (1996) 0.79
The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol Cell Biol (1987) 0.79
Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. J Immunol (1991) 0.79